InsidersTradesSigma
Track the Spero Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Spero Therapeutics, Inc. has published 104 reports. Market capitalisation: €73m. The latest transaction was reported on 6 August 2026 (Attribution). Among the most active insiders: Aquilo Capital Management, LLC. The full history is accessible without an account.
104
Insider Decl.
n/a
Thresholds
€13m
17 ops.
Buy Volume
€4m
20 ops.
Sell Volume
36Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,462 of 29,065 companies
67.5
score / 100
Value53
Quality82
FCF yld-18%
Earn yld12%
EV/EBITDA10.2x
ROE19%
Gross mgn·
Net mgn14%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 August 2026
Declarations104 total
162,311 shares0Common StockSEC:0001807743-26-000007:0
10,000 sharesCommon StockSEC:0001193125-26-283202:0
10,000 sharesCommon StockSEC:0001193125-26-283245:0
18,652 shares@ US$2.3682.9% of flowCommon StockSEC:0001193125-26-043315:0
37,101 shares@ US$2.3640.1% of flowCommon StockSEC:0001193125-26-043336:0
68,000 shares0Common StockSEC:0001193125-26-038441:0
249,000 shares0Common StockSEC:0001193125-26-038184:0
40,270 shares@ US$2.3774.4% of flowCommon StockSEC:0001193125-25-278370:0
6,572 shares@ US$1.976.1% of flowCommon StockSEC:0000950170-25-112661:0
1,695 shares@ US$1.9737.2% of flowCommon StockSEC:0000950170-25-112659:0
20,000 shares0Common StockSEC:0000950170-25-087021:0
20,000 shares0Common StockSEC:0000950170-25-087020:0
20,000 shares0Common StockSEC:0000950170-25-087017:0
20,000 shares0Common StockSEC:0000950170-25-087015:0
20,000 shares0Common StockSEC:0000950170-25-087013:0
20,000 shares0Common StockSEC:0000950170-25-087010:0
20,000 shares0Common StockSEC:0000950170-25-087009:0
20,000 shares0Common StockSEC:0000950170-25-087008:0
185,000 shares0Common StockSEC:0000950170-25-064821:0
13,959 shares@ US$0.784.9% of flowCommon StockSEC:0000950170-25-014849:0
751,407 shares0Common StockSEC:0000950170-25-014850:0
266,139 shares0Common StockSEC:0000950170-25-014859:0
266,139 shares0Common StockSEC:0000950170-25-014866:0
23,351 shares@ US$1.31100.0% of flowCommon StockSEC:0000950170-24-125339:0
2,757 shares@ US$1.3511.5% of flowCommon StockSEC:0000950170-24-101993:0
25 of 104 declarations
关于 Spero Therapeutics, Inc.
Spero Therapeutics, Inc. 是一家临床阶段的生物制药公司，在纳斯达克（美国）上市，股票代码为SPRO。公司总部位于美国马萨诸塞州剑桥，成立于2013年，其战略围绕多重耐药（MDR）细菌感染和特定罕见疾病中未满足的医疗需求。从股票研究的角度来看，Spero最好被视为一家利基、催化剂驱动的生物技术公司，而非商业阶段的制药公司：估值主要与临床数据、监管里程碑、许可经济效益和资产负债表的持久性相关联。([sperotherapeutics.com](https://www.sperotherapeutics.com/about-us?utm_source=openai)) 其主要资产是tebipenem HBr，这是一种正在开发用于复杂性尿路感染（cUTI），包括肾盂肾炎的口服碳青霉烯类药物。Spero表示，它已授予GSK在除某些亚洲市场外的所有地区商业化tebipenem HBr的独家许可，这意味着该项目具有战略重要性，尽管Spero并非主要的商业运营商。产品线还包括SPR720，一种用于非结核分枝杆菌肺病（NTM-PD）的口服候选药物，但该开发项目在2a期分析未能支持目标特征后已暂停。SPR206是另一种针对MDR革兰氏阴性感染的抗感染资产，仍是更广泛科学特许经营的一部分，但并非公司近期的核心价值驱动因素。([sperotherapeutics.com](https://www.sperotherapeutics.com/pipeline?utm_source=openai)) 在竞争方面，Spero在抗感染领域占据了专业地位，专注于口服治疗选择有限且静脉注射护理仍是标准治疗的治疗领域。tebipenem HBr的战略吸引力在于，如果获得批准，它可能成为美国首个可用的口服碳青霉烯类药物，通过实现早期出院或完全避免住院来改变cUTI患者的治疗途径。Spero不与大型制药公司进行规模竞争；相反，它在差异化、临床概念验证和监管执行方面展开竞争。([sperotherapeutics.com](https://www.sperotherapeutics.com/pipeline?utm_source=openai)) 最近的进展集中在tebipenem HBr上。2025年5月，Spero和GSK宣布关键的3期PIVOT-PO试验达到了主要终点，并将因疗效而提前终止。随后，GSK于2025年12月向FDA提交了NDA重新提交申请，Spero在2026年发布的2025年年度报告中指出，FDA接受了该重新提交申请。因此，对于投资者而言，SPRO是纳斯达克（美国）的一家高贝塔医疗保健公司，其投资案例主要取决于tebipenem HBr的监管路径、与GSK的合作经济效益以及公司在评估其下一步产品线时保持财务灵活性的能力。([gsk.com](https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/?utm_source=openai))
